ETONNGMHealthcare·Drug Manufacturers - Specialty & Generic#35 in industry

Eton Pharmaceuticals, Inc.

Reports in 15d· 2026-05-12

+55.9% · 90d

$23.45

+0.43 (+1.87%)

After-Hours $23.45(+0.00)

News

No News Yet

Press releases and SEC filings for ETON will appear here as they are published.

Check back later for updates

Key Data

Market Cap$639.8M

Open$23.00

Prev Close$23.02

Day Range$22.66 – $23.93

52W Range$13.09 – $27.29

Volume245,749

P/E (TTM)—

EPS$-0.17

Dividend Yield—

Beta0.97

Profit Margin-5.76%

Revenue Growth82.70%

Price Target$39.33(+67.7%)

Next Earnings2026-05-12(15d)

Analyst Ratings

Strong Buy3 analysts

Buy 3Hold 0Sell 0

About

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Healthcare · Drug Manufacturers - Specialty & Generic

44 employees

www.etonpharma.com